@article{bed3f026d5aa46fcb6ee709e2ee17f6b,
title = "ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike",
author = "Krucoff, \{Mitchell W.\} and Davide Cao and Roxana Mehran",
note = "Funding Information: R. Mehran reports institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, Medtronic, Novartis Pharmaceuticals, OrbusNeich, Philips, Transverse Medical, and Zoll; personal fees from ACC, Boston Scientific, California Institute for Regenerative Medicine (CIRM), Cine-Med Research, Janssen, WebMD, and SCAI; consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, Concept Medical, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, and Philips; holding equity <1\% in Applied Therapeutics, Elixir Medical, STEL, and CONTROLRAD (spouse); and being a member of the Scientific Advisory Board for AMA, and Biosensors (spouse). The other authors have no conflicts of interest to declare.",
year = "2022",
month = aug,
doi = "10.4244/EIJ-E-22-00024",
language = "English",
volume = "18",
pages = "E448--E449",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Group",
number = "6",
}